Sugi Predict

Sugi Predict / Compounds / SCHEMBL764354

SCHEMBL764354

SCHEMBL764354

CCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ UGCG Q16739 15/20 0.78
▸ HTR1A P08908 1/20 0.78
▸ PTGS1 P23219 1/20 0.78
▸ OPRM1 P35372 1/20 0.78
▸ ACACB O00763 1/20 0.46
▸ TP53 P04637 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ NFKB1 P19838 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ MTOR P42345 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8267379 1.00 UGCG (0.78) UGCGHTR1APTGS1OPRM1ACACB
SCHEMBL13057247 0.99 UGCG (0.77) UGCGHTR1APTGS1OPRM1ACACB
SCHEMBL1088358 0.89 UGCG (0.71) UGCGHTR1APTGS1OPRM1
SCHEMBL14069053 0.89 UGCG (0.71) UGCGHTR1APTGS1OPRM1
SCHEMBL13081778 0.89 UGCG (0.71) UGCGHTR1APTGS1OPRM1
SCHEMBL1088846 0.89 UGCG (0.71) UGCGHTR1APTGS1OPRM1
SCHEMBL19287298 0.89 UGCG (0.98) UGCGHTR1APTGS1OPRM1TP53
Eliglustat SCHEMBL4057024 0.88 UGCG (1.00) UGCGHTR1APTGS1OPRM1TP53
Eliglustat SCHEMBL4058275 0.88 UGCG (1.00) UGCGHTR1APTGS1OPRM1TP53
SCHEMBL12091633 0.88 UGCG (1.00) UGCGHTR1APTGS1OPRM1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171507-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS GENZYME CORPORATION 2021-06-10 — — US disclosed
US-20190322649-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS GENZYME CORPORATION 2019-10-24 — — US disclosed
US-20170334888-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS GENZYME CORPORATION 2017-11-23 — — US disclosed
US-9546161-B2 Synthesis of UDP-glucose: N-acylsphingosine glucosyl transferase inhibitors GENZYME CORPORATION (US) 2017-01-17 — — US disclosed
US-20120296088-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYL TRANSFERASE INHIBITORS GENZYME CORPORATION 2012-11-22 — — US disclosed
US-8138353-B2 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors GENZYME CORPORATION (US) 2012-03-20 — — US disclosed
US-20110003987-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS GENZYME CORPORATION 2011-01-06 — — US disclosed
US-7763738-B2 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors GENZYME CORPORATION (US) 2010-07-27 — — US disclosed
US-7615573-B2 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2009-11-10 — — US disclosed
US-20080058514-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS HIRTH BRADFORD H 2008-03-06 — — US disclosed
US-7265228-B2 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors GENZYME CORPORATION (US) 2007-09-04 — — US disclosed
US-20030050299-A1 An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents GENZYME CORPORATION 2003-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120296088-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYL TRANSFERASE INHIBITORS UGCG, UGGT1, DPAGT1 UGCG 1/4885HTR1A 3523/4885PTGS1 2177/4885
US-20210171507-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS UGCG, UGGT1, DPAGT1 UGCG 1/4885HTR1A 3504/4885PTGS1 2317/4885
US-20170334888-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS UGCG, UGGT1, DPAGT1 UGCG 1/4885HTR1A 3504/4885PTGS1 2317/4885
US-20110003987-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS UGCG, UGGT1, DPAGT1 UGCG 1/4885HTR1A 3504/4885PTGS1 2317/4885
US-20080058514-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS UGCG, UGGT1, DPAGT1 UGCG 1/4885HTR1A 3504/4885PTGS1 2317/4885
US-20190322649-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS UGCG, UGGT1, DPAGT1 UGCG 1/4885HTR1A 3504/4885PTGS1 2317/4885
US-20030050299-A1 An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents UGCG, UGGT1, LCLAT1 UGCG 1/4885HTR1A 4236/4885PTGS1 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.